Biotech Roundup: Scangos’s Exit, Zafgen’s Shakeup, Jounce, Relypsa & More
JULY 22, 2016
It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment. —Bruce Bigelow profiled Dauntless Pharmaceuticals , a stealthy biotech company creator in San Diego forming single-drug startups. —San Francisco gene therapy startup Audentes Pharmaceuticals (NASDAQ: BOLD ) raised $75 million in an IPO , selling 5 million shares at $15 apiece, right in its projected range.